Author:
Sharma Rohini,Pillai Anjana,Marron Thomas Urban,Fessas Petros,Saeed Anwaar,Jun Tomi,Dharmapuri Sirish,Szafron David,Naqash Abdul Rafeh,Gampa Anuhya,Wang Yinghong,Khan Uqba,Muzaffar Mahvish,Lee Chieh‐Ju,Lee Pei‐Chang,Bulumulle Anushi,Paul Sonal,Bettinger Dominic,Hildebrand Hannah,Yehia Mohammed,Pressiani Tiziana,Kaseb Ahmed,Huang Yi‐Hsiang,Ang Celina,Kudo Masatoshi,Nishida Naoshi,Personeni Nicola,Rimassa Lorenza,Pinato David James
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference39 articles.
1. Sorafenib in advanced hepatocellular carcinoma;N Engl J Med,2008
2. Efficacy and safety of sorafenib in patients in the Asia‐Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double‐blind, placebo‐controlled trial;Lancet Oncol,2009
3. Lenvatinib versus sorafenib in first‐line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non‐inferiority trial;Lancet,2018
4. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open‐label, non‐comparative, phase 1/2 dose escalation and expansion trial;Lancet,2017
5. Pembrolizumab as second‐line therapy in patients with advanced hepatocellular carcinoma in KEYNOTE‐240: a randomized, double‐blind;Phase III Trial. J Clin Oncol,2020